Santiago Gisler,  —

Articles by Santiago Gisler

Phase 1 Trial Testing PLN-74809 Supports its Clinical Development for IPF Treatment, Pliant Announces

Pliant Therapeutics has successfully completed a Phase 1 clinical study assessing its investigational therapy PLN-74809 for idiopathic pulmonary fibrosis (IPF), with results supporting further clinical development of the compound. PLN-74809 is an oral small molecule that selectively inhibits integrins (signaling receptors) called αVβ6 and αVβ1. Results from earlier preclinical…

Veracyte’s Envisia Classifier Improves ILD/IPF Diagnosis, Study Says

Envisia Genomic Classifier — a non-invasive diagnostic test developed by Veracyte and used as a complement to high-resolution computed tomography (HRCT) imaging — improves diagnosis of interstitial lung disease (ILD) and idiopathic pulmonary fibrosis (IPF) compared with HRCT alone, according to a recent study. The findings were published…

Increased Honeycombing Areas a Prognostic Factor in IPF, Study Finds

Quantification of so-called honeycombing areas (patches of cystic spaces) in the lungs seen through high-resolution computed tomography (HRCT) may be a predictor of mortality in people with idiopathic pulmonary fibrosis (IPF), according to a retrospective analysis. The study, “Quantitative CT analysis of honeycombing area predicts mortality in…

Study Finds Increased Risk of PF Among World Trade Center Responders

Exposure to dust in the aftermath of the World Trade Center attacks increased the risk of pulmonary fibrosis (PF) among responders, according to an evaluation of self-reported surveys. Researchers found that higher levels of dust exposure were associated with increased PF incidence. The study, “Pulmonary Fibrosis among World Trade…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums